Cerebrolysin – User Manual & Dosage Protocol Guide

Cerebrolysin is a sterile injectable preparation containing a mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue, studied/used in some countries for neurologic conditions (e.g., stroke recovery, cognitive disorders). (Cochrane)

Disclaimer: Cerebrolysin is not approved in all countries (e.g., not approved for use in the U.S.). Where available, it is typically used under licensed medical supervision. (Springer)

Ampoules / Vials (Solution for Injection/Infusion)

A ready-to-use sterile solution, typically supplied in 1 mL, 5 mL, or 10 mL ampoules, with 30 mL and 50 mL vials available in some markets.

Cerebrolysin is described as a neurotrophic / neuroprotective peptide mixture investigated for effects on neuronal function and recovery pathways in brain injury and neurodegenerative models. (Springer)

Important

Dosing depends on the medical indication, severity of condition, country-specific labeling, and clinician judgment. The following reflects commonly referenced prescribing guidance for parenteral administration.

Route Limits (Reference Guidance)

• Intramuscular (IM): Up to 5 mL per administration.
• Intravenous (IV) Injection: Up to 10 mL, typically given as a slow IV injection.
• IV Infusion: 10–50 mL, usually administered as a slow IV infusion after dilution.
  

Course Length (Common Reference)

• Course-Based Therapy: Often administered daily for 10–20 days, followed by clinical reassessment.

Indication-Based Reference Ranges

• Mild Cases / General Neurologic Support: 1–5 mL per day, commonly via IM or IV injection.
• Cognitive Impairment / Dementia Syndromes: 5–30 mL per day, with IV infusion typically used for higher volumes.
• Acute Ischemic Stroke / Severe Presentations: 10–50 mL per day, generally administered by IV infusion when volumes exceed 10 mL.
• Traumatic Brain Injury: 5–50 mL per day, often delivered by IV infusion for higher doses.
  

Frequency Note

Some treatment approaches reduce dosing frequency to 2–3 times per week after the initial course, depending on clinical judgment and local practice guidelines.

Initiation

The first 1–3 doses are used to monitor tolerability and vital signs.

Active Course

Commonly 10–20 days, focused on tracking symptom improvement and functional outcomes.

Reassess / Repeat (if indicated)

Further treatment is clinician-directed, based on patient response and applicable local guidance.

Cerebrolysin is typically ready-to-use (not “reconstituted” like lyophilized peptides).

For IV infusion dosing, references indicate dilution in standard infusion solutions such as:

• 0.9% saline, Ringer’s solution, or 5% glucose (product guidance varies by country/leaflet). (Medica RCP)

Infusion is commonly administered slowly (e.g., ~20–60 minutes is referenced in some leaflets/handbooks). (Medica RCP)

• Route selection generally follows volume guidance (IM ≤5 mL; IV injection ≤10 mL; higher volumes via IV infusion). (Medica RCP)
• Use standard sterile technique and administer under medical supervision (especially for infusion therapy).

Ampoules / Vials

Store according to the manufacturer’s instructions, commonly protected from light by keeping the product in its original carton.

Because Cerebrolysin is used for neurologic indications, monitoring commonly includes:

• Vitals during infusion (BP/HR), hypersensitivity reactions
• Neurologic function endpoints relevant to indication
  Safety/benefit evidence varies by condition; systematic reviews have evaluated outcomes in acute stroke. (Cochrane)

Product: Cerebrolysin (injectable peptide/amino acid mixture) (Cochrane)
Category: Neurologic / Neurotrophic research & clinical use (market-dependent) (Springer)
Routes: IM (≤5 mL), IV injection (≤10 mL), IV infusion (10–50 mL diluted) (Medica RCP)
Common Course: Daily for 10–20 days (then reassess) (Idoc.pub)
Storage: Protect from light (per labeling) (Cerebrolysin)